Skip to main content
Top
Published in: International Journal of Hematology 3/2018

01-09-2018 | Original Article

Safety of intra-articular transplantation of lentivirally transduced mesenchymal stromal cells for haemophilic arthropathy in a non-human primate

Authors: Tsukasa Ohmori, Hiroaki Mizukami, Yuko Katakai, Sho Kawai, Hitoyasu Nakamura, Makoto Inoue, Tsugumine Shu, Hideharu Sugimoto, Yoichi Sakata

Published in: International Journal of Hematology | Issue 3/2018

Login to get access

Abstract

Joint bleeding and resultant arthropathy are major determinants of quality of life in haemophilia patients. We previously developed a mesenchymal stromal cell (MSC)-based treatment approach for haemophilic arthropathy in a mouse model of haemophilia A. Here, we evaluated the long-term safety of intra-articular injection of lentivirally transduced autologous MSCs in non-human primates. Autologous bone-marrow-derived MSCs transduced with a lentiviral vector expressing coagulation factor VIII (FVIII) were injected into the left knee joint of cynomolgus monkeys. We first conducted codon optimization to increase FVIII production in the cells. Lentiviral transduction of autologous MSCs resulted in a significant increase of FVIII in the culture supernatant before transplantation. We did not find any tumour generation around the knee structure at 11–16 months after injection by magnetic resonance imaging. The proviral sequence of the simian immunodeficiency virus lentiviral vector was not detected in the heart, lungs, spleen, liver, testis, or bone marrow by real-time quantitative PCR. We confirmed the long-term safety of intra-articular injection of transduced MSCs in a non-human primate. The procedure may be an attractive therapeutic approach for joint diseases in haemophilia patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Young G. New challenges in hemophilia: long-term outcomes and complications. Hematol Am Soc Hematol Educ Program. 2012;2012:362–8. Young G. New challenges in hemophilia: long-term outcomes and complications. Hematol Am Soc Hematol Educ Program. 2012;2012:362–8.
2.
go back to reference Srivastava A. Haemophilia care—beyond the treatment guidelines. Haemophilia. 2014;20(Suppl 4):4–10.CrossRefPubMed Srivastava A. Haemophilia care—beyond the treatment guidelines. Haemophilia. 2014;20(Suppl 4):4–10.CrossRefPubMed
3.
go back to reference Marijke van den Berg H. Preventing bleeds by treatment: new era for haemophilia changing the paradigm. Haemophilia. 2016;22(Suppl 5):9–13. Marijke van den Berg H. Preventing bleeds by treatment: new era for haemophilia changing the paradigm. Haemophilia. 2016;22(Suppl 5):9–13.
4.
go back to reference George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377:2215–27.CrossRefPubMedPubMedCentral George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377:2215–27.CrossRefPubMedPubMedCentral
5.
go back to reference Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377:2519–30.CrossRefPubMed Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377:2519–30.CrossRefPubMed
6.
go back to reference Nijdam A, Foppen W, van der Schouw YT, Mauser-Bunschoten EP, Schutgens RE, Fischer K. Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia. 2016;22:852–8.CrossRefPubMed Nijdam A, Foppen W, van der Schouw YT, Mauser-Bunschoten EP, Schutgens RE, Fischer K. Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia. 2016;22:852–8.CrossRefPubMed
7.
go back to reference Hanley J, McKernan A, Creagh MD, Classey S, McLaughlin P, Goddard N, et al. Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: a United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) guideline. Haemophilia. 2017;23:511–20.CrossRefPubMed Hanley J, McKernan A, Creagh MD, Classey S, McLaughlin P, Goddard N, et al. Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: a United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) guideline. Haemophilia. 2017;23:511–20.CrossRefPubMed
8.
go back to reference Pulles AE, Mastbergen SC, Schutgens RE, Lafeber FP, van Vulpen LF. Pathophysiology of hemophilic arthropathy and potential targets for therapy. Pharmacol Res. 2017;115:192–9.CrossRefPubMed Pulles AE, Mastbergen SC, Schutgens RE, Lafeber FP, van Vulpen LF. Pathophysiology of hemophilic arthropathy and potential targets for therapy. Pharmacol Res. 2017;115:192–9.CrossRefPubMed
9.
go back to reference Ohmori T, Mizukami H, Ozawa K, Sakata Y, Nishimura S. New approaches to gene and cell therapy for hemophilia. J Thromb Haemost. 2015;13(Suppl 1):S133-42.PubMed Ohmori T, Mizukami H, Ozawa K, Sakata Y, Nishimura S. New approaches to gene and cell therapy for hemophilia. J Thromb Haemost. 2015;13(Suppl 1):S133-42.PubMed
10.
go back to reference Kashiwakura Y, Ohmori T, Mimuro J, Yasumoto A, Ishiwata A, Sakata A, et al. Intra-articular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor VIII-deficient mice. J Thromb Haemost. 2012;10:1802–13.CrossRefPubMed Kashiwakura Y, Ohmori T, Mimuro J, Yasumoto A, Ishiwata A, Sakata A, et al. Intra-articular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor VIII-deficient mice. J Thromb Haemost. 2012;10:1802–13.CrossRefPubMed
11.
go back to reference Ishiwata A, Mimuro J, Kashiwakura Y, Niimura M, Takano K, Ohmori T, et al. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene. Thromb Res. 2006;118:627–35.CrossRefPubMed Ishiwata A, Mimuro J, Kashiwakura Y, Niimura M, Takano K, Ohmori T, et al. Phenotype correction of hemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine factor VIII gene. Thromb Res. 2006;118:627–35.CrossRefPubMed
12.
go back to reference Menzella HG. Comparison of two codon optimization strategies to enhance recombinant protein production in Escherichia coli. Microb Cell Fact. 2011;10:15.CrossRefPubMedPubMedCentral Menzella HG. Comparison of two codon optimization strategies to enhance recombinant protein production in Escherichia coli. Microb Cell Fact. 2011;10:15.CrossRefPubMedPubMedCentral
13.
go back to reference Mimuro J, Muramatsu S, Hakamada Y, Mori K, Kikuchi J, Urabe M, et al. Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter. Gene Ther. 2001;8:1690–7.CrossRefPubMed Mimuro J, Muramatsu S, Hakamada Y, Mori K, Kikuchi J, Urabe M, et al. Recombinant adeno-associated virus vector-transduced vascular endothelial cells express the thrombomodulin transgene under the regulation of enhanced plasminogen activator inhibitor-1 promoter. Gene Ther. 2001;8:1690–7.CrossRefPubMed
14.
go back to reference Ohmori T, Mimuro J, Takano K, Madoiwa S, Kashiwakura Y, Ishiwata A, et al. Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy. FASEB J. 2006;20:1522–4.CrossRefPubMed Ohmori T, Mimuro J, Takano K, Madoiwa S, Kashiwakura Y, Ishiwata A, et al. Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy. FASEB J. 2006;20:1522–4.CrossRefPubMed
15.
go back to reference McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 2013;121:3335–44.CrossRefPubMedPubMedCentral McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 2013;121:3335–44.CrossRefPubMedPubMedCentral
16.
go back to reference Ward NJ, Buckley SM, Waddington SN, Vandendriessche T, Chuah MK, Nathwani AC, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood. 2011;117:798–807.CrossRefPubMed Ward NJ, Buckley SM, Waddington SN, Vandendriessche T, Chuah MK, Nathwani AC, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood. 2011;117:798–807.CrossRefPubMed
17.
go back to reference Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011;9:CD003429. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011;9:CD003429.
18.
go back to reference Arruda VR, Doshi BS, Samelson-Jones BJ. Novel approaches to hemophilia therapy: successes and challenges. Blood. 2017;130:2251–6.CrossRefPubMed Arruda VR, Doshi BS, Samelson-Jones BJ. Novel approaches to hemophilia therapy: successes and challenges. Blood. 2017;130:2251–6.CrossRefPubMed
19.
go back to reference Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415–9.CrossRefPubMed Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415–9.CrossRefPubMed
20.
go back to reference McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2004;350:913–22.CrossRefPubMed McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2004;350:913–22.CrossRefPubMed
21.
go back to reference Cavazzana M, Six E, Lagresle-Peyrou C, Andre-Schmutz I, Hacein-Bey-Abina S. Gene therapy for X-linked severe combined immunodeficiency: where do we stand? Hum Gene Ther. 2016;27:108–16.CrossRefPubMedPubMedCentral Cavazzana M, Six E, Lagresle-Peyrou C, Andre-Schmutz I, Hacein-Bey-Abina S. Gene therapy for X-linked severe combined immunodeficiency: where do we stand? Hum Gene Ther. 2016;27:108–16.CrossRefPubMedPubMedCentral
22.
go back to reference Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, Sellers S, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2004;2:e423.CrossRefPubMedPubMedCentral Hematti P, Hong BK, Ferguson C, Adler R, Hanawa H, Sellers S, et al. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells. PLoS Biol. 2004;2:e423.CrossRefPubMedPubMedCentral
23.
go back to reference Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24:687–96.CrossRefPubMed Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24:687–96.CrossRefPubMed
24.
go back to reference Alton EW, Beekman JM, Boyd AC, Brand J, Carlon MS, Connolly MM, et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax. 2017;72:137–47.CrossRefPubMed Alton EW, Beekman JM, Boyd AC, Brand J, Carlon MS, Connolly MM, et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis. Thorax. 2017;72:137–47.CrossRefPubMed
25.
go back to reference Ikeda Y, Yonemitsu Y, Miyazaki M, Kohno R, Murakami Y, Murata T, et al. Acute toxicity study of a simian immunodeficiency virus-based lentiviral vector for retinal gene transfer in nonhuman primates. Hum Gene Ther. 2009;20:943–54.CrossRefPubMed Ikeda Y, Yonemitsu Y, Miyazaki M, Kohno R, Murakami Y, Murata T, et al. Acute toxicity study of a simian immunodeficiency virus-based lentiviral vector for retinal gene transfer in nonhuman primates. Hum Gene Ther. 2009;20:943–54.CrossRefPubMed
26.
go back to reference Ireland H, Gay MHP, Baldomero H, De Angelis B, Baharvand H, Lowdell MW, et al. The survey on cellular and tissue-engineered therapies in Europe and neighboring Eurasian countries in 2014 and 2015. Cytotherapy. 2018;20(1):1–20.CrossRefPubMed Ireland H, Gay MHP, Baldomero H, De Angelis B, Baharvand H, Lowdell MW, et al. The survey on cellular and tissue-engineered therapies in Europe and neighboring Eurasian countries in 2014 and 2015. Cytotherapy. 2018;20(1):1–20.CrossRefPubMed
27.
go back to reference Porada CD, Sanada C, Kuo CJ, Colletti E, Mandeville W, Hasenau J, et al. Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. Exp Hematol. 2011;39:1124–35 e4.CrossRefPubMedPubMedCentral Porada CD, Sanada C, Kuo CJ, Colletti E, Mandeville W, Hasenau J, et al. Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. Exp Hematol. 2011;39:1124–35 e4.CrossRefPubMedPubMedCentral
28.
go back to reference Sokal EM, Lombard CA, Roelants V, Najimi M, Varma S, Sargiacomo C, et al. Biodistribution of liver-derived mesenchymal stem cells after peripheral injection in a hemophilia A patient. Transplantation. 2017;101:1845–51.CrossRefPubMed Sokal EM, Lombard CA, Roelants V, Najimi M, Varma S, Sargiacomo C, et al. Biodistribution of liver-derived mesenchymal stem cells after peripheral injection in a hemophilia A patient. Transplantation. 2017;101:1845–51.CrossRefPubMed
Metadata
Title
Safety of intra-articular transplantation of lentivirally transduced mesenchymal stromal cells for haemophilic arthropathy in a non-human primate
Authors
Tsukasa Ohmori
Hiroaki Mizukami
Yuko Katakai
Sho Kawai
Hitoyasu Nakamura
Makoto Inoue
Tsugumine Shu
Hideharu Sugimoto
Yoichi Sakata
Publication date
01-09-2018
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2465-8

Other articles of this Issue 3/2018

International Journal of Hematology 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine